Can a breast cancer drug reach brain tumors? new study aims to find out
NCT ID NCT06058988
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how much of the drug T-DXd enters brain tumors in people with HER2-positive brain cancers or glioblastoma. Thirty participants will receive T-DXd before surgery to remove a brain tumor, and researchers will measure drug levels in the tumor. The goal is to see if T-DXd can effectively target these hard-to-treat cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trastuzumab deruxtecan (T-DXd)
- What this could lead to
- If successful, this could show that T-DXd reaches brain tumors effectively, pointing toward a new treatment option for HER2-positive brain cancers.
- What could go wrong
- This is a small, early-phase study focused on drug penetration, not yet proving the drug works. Results may not lead to a treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRAIN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New imaging clues could sharpen brain tumor monitoring
- Can a virus injected into brain tumors fight recurrence?
- Can a Tumor's genetic blueprint guide better treatment for kids with brain cancer?
- Can a seizure drug outsmart a deadly brain tumor?
- A simple lotion duo may shield skin from Tumor-Treating fields
- Tissue analysis may guide personalized cancer therapy